Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequence of Endocrine Therapy and Capecitabine in Metastatic Breast Cancer
NCT00684216Phase 3Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2008
- Primary completion
- May 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Quality of Life. Started Apr 2008; status: terminated.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00684216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684216.